SCHEMBL2377484

SCHEMBL2377484

CN(CCN1CCOCC1)C(=O)c1ccc(Br)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
MPI P34949 1/20 0.43
MEN1 O00255 4/20 0.43
HTT P42858 1/20 0.43
DRD4 P21917 1/20 0.41
TACR1 P25103 1/20 0.41
TACR3 P29371 1/20 0.41
MAPK1 P28482 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
TSHR P16473 1/20 0.40
CD274 Q9NZQ7 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378980 0.87 MAPK1 (0.49) KMT2AALDH1A1MAPTLMNAMPI
SCHEMBL28037481 0.77 ALDH1A1 (0.58) KMT2AALDH1A1MAPTLMNATACR1
SCHEMBL40396 0.77 CASR (0.51) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL18348174 0.77 PDK2 (0.47) HTT
SCHEMBL10110634 0.77 GRIA3 (0.44) KMT2AALDH1A1MEN1DRD4TACR1
SCHEMBL2957152 0.76 ALDH1A1 (0.65) KMT2AALDH1A1MAPTLMNAMPI
SCHEMBL12505784 0.76 DRD4 (0.50) KMT2AALDH1A1MAPTMEN1DRD4
SCHEMBL40051 0.76 DRD4 (0.53) KMT2AALDH1A1MAPTLMNAMEN1
Hydrochloric Acid SCHEMBL561716 0.76 GRIA3 (0.43) KMT2AALDH1A1MAPTLMNAMPI
SCHEMBL2249033 0.76 HIF1A (0.50) KMT2AALDH1A1MAPTCD274SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 KMT2A 2799/4885ALDH1A1 2102/4885MAPT 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.